Approved for the use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to a co ction of information unless it displays a valid OMB control

ERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE **PATENTING**

Docket Number (optional) 219002028402 REJECTION OVER A PENDING SECOND APPLICATION

In re Application of:

Sarvajit CHAKRAVARTY, et al.

Application No.:

Filed:

For:

Not yet assigned

Herewith

QUINAZOLINE DERIVATIVES AS MEDICAMENTS

The owner Scios, Inc., of 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer of prior Application Serial No. 09/383,825. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is attorney or agent of record.

Terminal disclaimer fee of \$ under 37 C.F.R. 1.20(d) is included.

 \boxtimes Please charge the terminal disclaimer fee of \$110.00 to Deposit Account 03-1952.

> WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

*Statement under 37 CFR 3.73 (b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

HINATO THE COUNTY OF SECUNDARY OF THE COMPLETE. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you ulred to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington D.C 20231. DO NOT SEND FEES OR COMPLETED THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington D.C 20231.